2curex co-founder wants to combat autoimmune diseases with nanotechnology
Timm Jessen co-founded 2curex in 2006 and is now CEO of Topas, a German biotech company using nanotechnology for developing drugs against autoimmune diseases. The company aims to take a candidate against a rare skin disorder to the clinic in 2019 and follow up with a diabetes therapy in 2020.
In 2006, Timm Jessen spun out 2curex from the Calrsberg laboratories, but since 2015 he has been in charge of the German biotech company Topas Therapeutics.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
2curex CEO after IPO: ”It’s pretty crazy”
For abonnenter
